Global Post-Traumatic Stress Disorder Treatment Market Overview
According to SPER Market Research, the Global Post-Traumatic Stress Disorder Treatment Market is estimated to reach USD 27.77 billion by 2032 with a CAGR of 5.14%.
A psychiatric ailment called post-traumatic stress disorder (PTSD) can develop in people who have experienced a severe shock like a natural disaster, a life-threatening situation, a vehicle accident, sexual abuse, etc. PTSD symptoms can start to manifest three months or even a year later. Most PTSD sufferers exhibit symptoms like intrusive memories, avoidance, unfavourable thinking changes, and altered emotional and physical responses. For instance, PTSD in some people may be brought on by the abrupt death of a loved one. Danger perception is heightened in PTSD patients.The market is primarily driven by a strong late-stage product pipeline and rising R&D for the creation of novel medical regimens. The market is primarily being driven by the increase in post-traumatic stress disorder (PTSD) cases around the world.Lack of knowledge about post-traumatic stress disorder may hinder the expansion of the global market for its treatment. The market for treating post-traumatic stress disorder is severely constrained by the high cost of care.The prevalence of post-traumatic stress disorder (PTSD) is rising globally, there are more clinical studies being conducted to treat PTSD, and there has been an increase in the development of new PTSD treatments and medications, all of which have contributed to the market's expansion.
Impact of COVID-19 on the Global Post-Traumatic Stress Disorder Treatment Market
The market for treating posttraumatic stress disorder (PTSD) has been dramatically impacted by the extraordinary health problem known as the COVID-19 pandemic. Numerous researches have been done that show COVID-19 increases the risk of PTSD, which has increased demand for PTSD therapy. For instance, a review article titled "COVID-19 and posttraumatic stress disorder: The perfect "storm" for mental health" showed that COVID-19 has a significant effect on mental health and poses a significant risk for the emergence of trauma-related disorders, including PTSD, among those who are most vulnerable, such as children, adolescents, and COVID-19 survivors. Thus, the COVID-19 pandemic has positively impacted market growth.
Scope of the Report:
| Report Metric | Details |
| Market size available for years | 2019-2032 |
| Base year considered | 2021 |
| Forecast period | 2022-2032 |
| Segments covered | By Drug Type, By Age Group, By Distribution Channel, By End User |
| Regions covered | North America, Europe, Asia Pacific, Latin America, Middle East and Africa |
| Companies Covered | Allergan PLC, Amneal Pharmaceuticals LLC, Apotex Inc., AstraZeneca, Aurobindo Pharma, Bausch Health Companies Inc., Bristol-Myers Squibb, Eli Lilly and Company, GlaxoSmithKline PLC, Johnson and Johnson, Mylan Pharmaceuticals, Pfizer Inc., Sun Pharmaceuticals Pvt Ltd, Teva Pharmaceuticals Industries Ltd. |
Key Audience
- Hospitals
- Mental Health Centre
- Outpatient Clinics
Global Post-Traumatic Stress Disorder Treatment Market Segmentation:
1. By Drug Type:
- Anti-anxiety
- Antidepressants
- Antipsychotics
- Beta-blockers
- Monoamine Oxidase
- Others
2. By Age Group:
- Paediatrics
- Geriatrics
- Adults
3. By Distribution Channel:
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
4. By End User:
- Mental Health Center
- Hospitals
- Outpatient Clinics
- Others
5. By Region:
- Asia-Pacific
- Europe
- Middle East & Africa
- North America
- South America
Key Topics Covered in the Report:- Size of Global Post-Traumatic Stress Disorder Treatment Market (FY’2019-FY’2032)
- Overview of Global Post-Traumatic Stress Disorder Treatment Market
- Segmentation of Global Post-Traumatic Stress Disorder Treatment Market By Drug Type (Anti-anxiety, Antidepressants, Antipsychotics, Beta-blockers, Monoamine Oxidase, Others)
- Segmentation of Global Post-Traumatic Stress Disorder Treatment Market By Age Group (Paediatrics, Geriatrics, Adults)
- Segmentation of Global Post-Traumatic Stress Disorder Treatment Market By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies)
- Segmentation of Global Post-Traumatic Stress Disorder Treatment Market By End User (Mental Health Centre, Hospitals, Outpatient Clinics, Others)
- Statistical Snap of Global Post-Traumatic Stress Disorder Treatment Market
- Growth Analysis of Global Post-Traumatic Stress Disorder Treatment Market
- Problems and Challenges in Global Post-Traumatic Stress Disorder Treatment Market
- Competitive Landscape in the Global Post-Traumatic Stress Disorder Treatment Market
- Impact of COVID-19 and Demonetization on Global Post-Traumatic Stress Disorder Treatment Market
- Details on Recent Investment in Global Post-Traumatic Stress Disorder Treatment Market
- Competitive Analysis of Global Post-Traumatic Stress Disorder Treatment Market
- Major Players in the Global Post-Traumatic Stress Disorder Treatment Market
- SWOT Analysis of Global Post-Traumatic Stress Disorder Treatment Market
- Global Post-Traumatic Stress Disorder Treatment Market Future Outlook and Projections (FY’2019-FY’2032)
- Recommendations from Analyst
1. Introduction
1.1. Scope of the report
1.2. Market segment analysis
2. Research Methodology
2.1 Research data source
2.1.1 Secondary data
2.1.2 Primary data
2.1.3 SPER’s internal database
2.1.4 Premium insight from KOL’s
2.2 Market size estimation
2.2.1 Top-down and Bottom-up approach
2.3 Data triangulation
3. Executive Summary
4. Market Dynamics
4.1. Driver, Restraint, Opportunity and Challenges analysis
4.1.1 Drivers
4.1.2 Restraints
4.1.3 Opportunities
4.1.4 Challenges
4.2. COVID-19 Impacts of the Global Post-Traumatic Stress Disorder Treatment Market
5. Market variables and outlook
5.1. SWOT analysis
5.1.1 Strengths
5.1.2 Weaknesses
5.1.3 Opportunities
5.1.4 Threats
5.2. PESTEL analysis
5.2.1 Political landscape
5.2.2 Economic landscape
5.2.3 Social landscape
5.2.4 Technological landscape
5.2.5 Environmental landscape
5.2.6 Legal landscape
5.3. PORTER’S five forces analysis
5.3.1 Bargaining power of suppliers
5.3.2 Bargaining power of Buyers
5.3.3 Threat of Substitute
5.3.4 Threat of new entrant
5.3.5 Competitive rivalry
5.4. Heat map analysis
6. Competitive Landscape
6.1 Global Post-Traumatic Stress Disorder Treatment Manufacturing Base Distribution, Sales Area, Product Type
6.2 Mergers & Acquisitions, Partnerships, Product Launch, and Collaboration in Global Post-Traumatic Stress Disorder Treatment Market
7. Global Post-Traumatic Stress Disorder Treatment Market, By DrugType, 2019-2032 (USD Million)
7.1 Anti-anxiety
7.2 Antidepressants
7.3 Antipsychotics
7.4 Beta-blockers
7.5 Monoamine Oxidase
7.6 Others
8. Global Post-Traumatic Stress Disorder Treatment Market, By Age Group, 2019-2032 (USD Million)
8.1 Paediatrics
8.2 Geriatrics
8.3 Adults
9. Global Post-Traumatic Stress Disorder Treatment Market, By Distribution Channel, 2019-2032 (USD Million)
9.1 Hospital Pharmacies
9.2 Retail Pharmacies
9.3 Online Pharmacies
10. Global Post-Traumatic Stress Disorder Treatment Market, By End User, 2019-2032 (USD Million)
10.1 Mental Health Center
10.2 Hospitals
10.3 Outpatient Clinics
10.4 Others
11. Global Post-Traumatic Stress Disorder Treatment Market, By Region, 2019-2032 (USD Million)
11.1 Global Post-Traumatic Stress Disorder Treatment Size and Market Share by Region (2019-2025)
11.2 Global Post-Traumatic Stress Disorder Treatment Size and Market Share by Region (2026-2032)
11.3 Asia-Pacific
11.3.1 Australia
11.3.2 China
11.3.3 India
11.3.4 Japan
11.3.5 South Korea
11.3.6 Rest of Asia-Pacific
11.4 Europe
11.4.1 France
11.4.2 Germany
11.4.3 Italy
11.4.4 Spain
11.4.5 United Kingdom
11.4.6 Rest of Europe
11.5 Middle East & Africa
11.5.1 Kingdom of Saudi Arabia
11.5.2 United Arab Emirates
11.5.3 Rest of Middle East & Africa
11.6 North America
11.6.1 Canada
11.6.2 Mexico
11.6.3 United States
11.7 South America
11.7.1 Argentina
11.7.2 Brazil
11.7.3 Rest of South America
12. Company Profiles
12.1 Allergan PLC
12.1.1 Company details
12.1.2 Financial outlook
12.1.3 Product summary
12.1.4 Recent developments
12.2 Amneal Pharmaceuticals LLC
12.2.1 Company details
12.2.2 Financial outlook
12.2.3 Product summary
12.2.4 Recent developments
12.3 Apotex Inc.
12.3.1 Company details
12.3.2 Financial outlook
12.3.3 Product summary
12.3.4 Recent developments
12.4 AstraZeneca
12.4.1 Company details
12.4.2 Financial outlook
12.4.3 Product summary
12.4.4 Recent developments
12.5 Aurobindo Pharma
12.5.1 Company details
12.5.2 Financial outlook
12.5.3 Product summary
12.5.4 Recent developments
12.6 Bausch Health Companies Inc.
12.6.1 Company details
12.6.2 Financial outlook
12.6.3 Product summary
12.6.4 Recent developments
12.7 Bristol-Myers Squibb
12.7.1 Company details
12.7.2 Financial outlook
12.7.3 Product summary
12.7.4 Recent developments
12.8 Eli Lilly and Company
12.8.1 Company details
12.8.2 Financial outlook
12.8.3 Product summary
12.8.4 Recent developments
12.9 GlaxoSmithKline PLC
12.9.1 Company details
12.9.2 Financial outlook
12.9.3 Product summary
12.9.4 Recent developments
12.10 Johnson and Johnson
12.10.1 Company details
12.10.2 Financial outlook
12.10.3 Product summary
12.10.4 Recent developments
12.11 Mylan Pharmaceuticals
12.11.1 Company details
12.11.2 Financial outlook
12.11.3 Product summary
12.11.4 Recent developments
12.12 Pfizer Inc.
12.12.1 Company details
12.12.2 Financial outlook
12.12.3 Product summary
12.12.4 Recent developments
12.13 Sun Pharmaceuticals Pvt Ltd
12.13.1 Company details
12.13.2 Financial outlook
12.13.3 Product summary
12.13.4 Recent developments
12.14 Teva Pharmaceuticals Industries Ltd.
12.14.1 Company details
12.14.2 Financial outlook
12.14.3 Product summary
12.14.4 Recent developments
13. List of Abbreviations
14. Reference Links
15. Conclusion
16. Research Scope